Chris has overall responsibility for managing the Company’s business development efforts for cancer products. He has over 15 years’ experience in the pharmaceutical and biotech industries with the last 6 years in the development and commercialisation of biomarkers for the early detection and screening of cancer. He is a co-founder of Abcodia Ltd, a clinical stage company engaged in the commercial development of novel, validated tests for the early detection of cancer. The Company's first product for the early detection of ovarian cancer was launched in the UK and US in 2015. Prior to Abcodia he was the Chief Operating Officer at BioWisdom, a Cambridge based company that provided a suite of software tools for the acquisition, integration, visualization and high-value analysis of healthcare intelligence to support the drug development process.